Oxford BioTherapeutics appoints new chief operations officer
pharmafile | May 3, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Oxford Biotherapeutics
Oxford BioTherapeutics (OBT) has appointed Dr Esteban Pombo-Villar as its new chief operations officer (COO).
In this position he will lead the company’s newly created clinical development operations based in Basel, Switzerland.
Pombo-Villar will also become an executive member of OBT’s Board.
Prior to joining OBT, Pombo-Villar worked at Novartis for over 20 years, the last 12 years of which he focused on all aspects of creating and managing alliances.
Most recently he was head of alliance management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept in man.
He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel, in 1988.
At Sandoz, he worked on drug discovery projects as well as leading collaborative projects investigating the potential of emerging technologies.
Related Content

Tech platform company WuXi Biologics inks deal with cancer specialist Oxford BioTherapeutics worth $450m
Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology …
Sanofi buys into cancer antibody research
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) …
GSK signs oncology deal with UK biotech
GSK has struck a deal with Oxford BioTherapeutics to develop therapies for primary, metastatic and …






